We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
- Authors
Abad, Albert; Massutí, Bartomeu; Antón, Antonio; Vega, Ma. Eugenia; Yuste, Ana L.; Marcuello, Eugenio; Manzano, José Luis; Alonso, Vicente; Carrato, Alfredo; Martinez-Villacampa, Mercedes; Tabernero, J.; Aranda, Enrique; Rivera, Fernando; Díaz-Rubio, Eduardo
- Abstract
Purpose. To investigate the response rate of the triple combination of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) and 5-fluorouracil (5-FU) and to assess its impact on secondary resectability of previously non-resectable liver metastasis (LM). Patients and methods. Patients≥18 with MCRC, ECOG grade 0-2, and no prior treatment received L-OHP (85 mg/m2), CPT-11 (150 mg/m2) and 5-FU (2 250 mg/m2 in 48 h CI) on D1 every 15 days. Results. Forty-seven patients with initially non-resectable metastatic disease were included. Median age 62 years (38-76); 28 males; 26 patients with 0 performance status (ECOG) 40 patients had prior surgery and four adjuvant chemotherapy. All patients were evaluable for toxicity and 42 for response. Main grade 3-4 toxicities were neutropenia (40%), febrile neutropenia (4%), diarrhea (21%), nausea/vomiting (11%/15%), fatigue (11%), anemia and alopecia (9% each); grade 3-4 neurotoxicity was observed in 28% patients. Secondary surgery was possible in 15 of 47 (31.9%) patients and 12/30 (40%) patients with only LM: in this cohort, median OS has not been reached at 22 months median follow-up, with 2/12 patients having died. Overall response rate was 69% (95% CI, 53-82%); 13 (31%) had stable disease. Median time to progression and overall survival (OS) were 10.9 (95% CI, 9.9-13.2) and 19.9 (95% CI, 11.7-TBD) months, respectively. Conclusion. This combination has shown promising activity with manageable toxicity as front-line treatment in MCRC, and has allowed the resectability of LM in a considerable number of patients, offering them the possibility of long-term survival.
- Subjects
COLON cancer treatment; CANCER treatment; METASTASIS; OXALIPLATIN; ANTINEOPLASTIC agents; ORGANOPLATINUM compounds; FLUOROURACIL
- Publication
Acta Oncologica, 2008, Vol 47, Issue 2, p286
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/02841860701630259